Novavax (NVAX) Short-term Investments (2010 - 2026)

Novavax's Short-term Investments history runs 15 years deep, the most recent figure standing at $562.0 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 20.05% year-over-year to $562.0 million in Q1 2026; TTM through Mar 2026 was $562.0 million, a 20.05% increase from a year earlier, with the FY2025 full-year figure at $494.4 million, up 25.85% from the prior year.
• Short-term Investments climbed to $562.0 million in Q1 2026 per NVAX's latest filing, from $494.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $562.0 million in Q1 2026 and bottomed at $335.9 million in Q3 2024.
• The 3-year median for Short-term Investments is $430.5 million (2024), against an average of $434.5 million.
• Biggest YoY gain for Short-term Investments was 47.33% in 2025; the steepest drop was 2.94% in 2025.
• Year by year, Short-term Investments stood at $392.9 million in 2024, then gained by 25.85% to $494.4 million in 2025, then gained by 13.66% to $562.0 million in 2026.
• Per Business Quant, the three latest NVAX Short-term Investments figures stand at $562.0 million (Q1 2026), $494.4 million (Q4 2025), and $494.9 million (Q3 2025).